1 May 2011

Contents

Conference reports

• 17th Annual Conference of the British HIV Association (BHIVA), 6-8 April 2011, Bournemouth

• Atazanavir in pregnancy: 155 cases in London clinics

• Co-morbidity and late presentation – findings from an over 50s cohort

• Health outcomes for young adults with perinatally acquired HIV infection following transfer to adult services

• The use of calcaneal stiffness index to screen for osteoporosis in HIV-infected individuals

• Frequency and characteristics of long-term non-progressors and HIV controllers in the Chelsea and Westminster cohort

• Cerebral function in perinatally HIV infected young people and HIV uninfected sibling controls

• An audit of HIV care provision for Immigration Removal Centre patients

• 12th International Workshop on Clinical Pharmacology of HIV Therapy, 13–-15 April 2011, Miami

• Quad reduces levels of oral contraceptives

• Elvitegravir/cobicistat and acid reducing agents

• Lopinavir/r reduces levels of rifabutin

• Cobicistat has little impact on CYP2D6 and CYP2B6

• Atazanavir levels indicate need for higher dose during pregnancy

• Etravirine lowers levels of maraviroc given at 300 or 600 mg twice daily

• Once-daily 150-mg maraviroc explored in people taking atazanavir/ritonavir

• Lopinavir troughs lower in children on once-daily dose with efavirenz

• Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily

• 46th European Association for the Study of the Liver (EASL), 30 March-3 April 2011, Berlin, Germany

• Rapid report: state of HCV policy, treatment, access

• 18th Conference on Retroviruses and Opportunistic Infections (CROI), 27 February–-3 March 2011, Boston

• When to start ART in patients co-infected with TB: results from two trials presented at CROI

• Inflammation and intervention: how does HIV cause AIDS and how does it cause disease despite ART

PK and drug interactions

• Meeting report from 12th Pharmacology Workshop, Miami

• Meeting report from 18th CROI, Boston

• Atazanavir/ritonavir and combined oral contraceptives

Side effects

• Tenofovir associated with fewer side-effect related switches compared to AZT or d4T in first-line treatment

HIV prevention and transmission

• FEM-PrEP prevention study using daily Truvada halted during enrolment: interim analysis shows similar infection rates in active and placebo arms

Basic science and immunology

• Reduced HIV replication in CD4 T cells from elite controllers

• More studies on the loss of naive T cells

• The immunological effects of old age and anti-CMV immunity in HIV infection

BHIVA news

• BASHH/BHIVA PEPSE guidelines for comment (2011)

• UK national guideline on safer sex advice

On the web

• Community resources and publications

PDFs

• Volume 12 Number 5/6 May/June 2011 PDF